Biotech company closes heavily oversubscribed financing round

More than 70 investors participated in biotech company Synklino's financing round with proceeds going to the drug development for organ transplant patients infected with the herpesvirus cytomegalovirus (CMV).
Thomas N. Kledal, co-founder and CEO at Synklione (to the right) and John Haurum, chairman of the board of Synklino. | Photo: Synklino / PR
Thomas N. Kledal, co-founder and CEO at Synklione (to the right) and John Haurum, chairman of the board of Synklino. | Photo: Synklino / PR
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN

Finding the necessary capital to continue operations has been smooth sailing for biotech company Synklino, which reported on Monday that a financing round has concluded, bringing in DKK 106m (USD 16.2m).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading